Who
Paul M. Silva
Director
Company insider
Files Form 4 as: Director, Rapport Therapeutics; Director, Nurix Therapeutics; SVP & Chief Accounting Officer, Vertex Pharmaceuticals.
In numbers
- Trades disclosed
- 571
- Buys
- 0
- Sells
- 116
- Bought
- $0
- Sold
- $51.1M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 18 Nov 2008
- Last trade
- 10 Jun 2026
- Last filed
- 10 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 10 Jun 2026 | RAPP Rapport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,200 at $0.00 | filing |
| 10 Jun 2026filed 10 Jun 2026 | RAPP Rapport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,200 at $0.00 | filing |
| 15 May 2026filed 15 May 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,250 at $0.00 | filing |
| 15 May 2026filed 15 May 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,250 at $0.00 | filing |
| 17 Jun 2025filed 18 Jun 2025 | RAPP Rapport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,925 at $0.00 | filing |
| 19 May 2025filed 19 May 2025 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 7 Nov 2024filed 7 Nov 2024 | RAPP Rapport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,756 at $0.00 | filing |
| 20 May 2024filed 20 May 2024 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 4 May 2023filed 4 May 2023 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 5 May 2022filed 6 May 2022 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 1 Oct 2021filed 4 Oct 2021 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 1 Mar 2021filed 2 Mar 2021 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $216K1,026 at $210.13 | filing |
| 1 Mar 2021filed 2 Mar 2021 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $129K610 at $211.45 | filing |
| 1 Mar 2021filed 2 Mar 2021 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $194K915 at $212.51 | filing |
| 1 Mar 2021filed 2 Mar 2021 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $49K231 at $213.12 | filing |
| 26 Feb 2021filed 2 Mar 2021 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $471K2,218 at $212.42 | filing |
| 25 Feb 2021filed 26 Feb 2021 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $52K244 at $211.80 | filing |
| 25 Feb 2021filed 26 Feb 2021 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $96K452 at $213.12 | filing |
| 25 Feb 2021filed 26 Feb 2021 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $55K258 at $214.32 | filing |
| 25 Feb 2021filed 26 Feb 2021 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $27K126 at $216.25 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Head to Head Analysis: Caribou Biosciences (NASDAQ:CRBU) & Vertex Pharmaceuticals (NASDAQ:VRTX)VRTX · tickerreport.com · 14 Oct 2026Vertex Pharmaceuticals Incorporated: Vertex to Present New Data on ALYFTREK at the North American Cystic Fibrosis ConferenceVRTX · finanznachrichten.de · 9 Oct 2026
0 headlines in the last 90 days name Paul M. Silva; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.